Recent research spearheaded by Lisa Bodei, MD and published in the Journal of Nuclear Medicine (April '23) has validated the role of the NETest as a predictor of the effectiveness of PRRT in treating NETs.
The NETest PPQ–Peptide Receptor Radionuclide Therapy Predictor Quotient–exhibits over 97% accuracy in predicting positive response to PRRT for metastatic/inoperable NETs in real time.
Recent Memorial Sloan Kettering Cancer Center research published in the Journal of Nuclear Medicine (April '23) has validated the NETest and PPQ as a predictor of PRRT effectiveness in treating some NETs.
Blood-based genomic assessment is 90% accurate in predicting PRRT treatment response for NETs.
We developed a complementary diagnostic based on circulating gene expression measurements (Ome index) and grading which can be used to predict response to PRRT. The accuracy of this Prediction Quotient in this discovery cohort of 54 NETs was 94%...
NET patients are increasingly treated with peptide receptor radionuclide therapy. Somatostatin receptor expression evaluation cannot predict who will respond to therapy. But research indicates NETest PPQ can predict PRRT response.
We validated the PRRT Prediction Quotient (PPQ) as a complementary diagnostic in two different PRRT cohorts. The validation cohort prediction accuracy was 95%; significantly more predictive than either grade (70%) or elevated chromogranin A (50%).
